Status:
COMPLETED
Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
A broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage breast cancer. These range from free and publicly available mathematical algorithms, throug...
Detailed Description
A broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage hormone receptor positive, Her2 negative breast cancer. These range from free and publicly ...
Eligibility Criteria
Inclusion
- Histologically confirmed primary breast cancer
- No prior chemotherapy
- Eligible for Oncotype DX ® testing as per current Ontario funding criteria including: ER positive, PR positive or negative, HER2 negative, lymph node status negative or micro-invasive disease, tumor \>1 cm in size (or if equal or \<1 cm, must be grade 2/3 or have lymph node micrometastasis).
Exclusion
- Neoadjuvant treatment including window of opportunity trials
- Recurrent breast cancer
Key Trial Info
Start Date :
March 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2022
Estimated Enrollment :
602 Patients enrolled
Trial Details
Trial ID
NCT04131933
Start Date
March 6 2020
End Date
May 18 2022
Last Update
December 23 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L 2V7
2
Grand River Hospital
Kitchener, Ontario, Canada, N2G 1G3
3
Markham Stouffville Hospital
Markham, Ontario, Canada, L3P 7P3
4
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada